SpyGlass Pharma, Inc.

The Company expects to seek additional funding through equity financings, debt financings or other sources.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The Company repurchased 174,432 shares of its common stock at $ 8.31 per share in June 2025.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The repurchased common stock was retired and returned to the status of authorized and unissued shares.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Dividend yield of zero The Company has not, and does not, intend to pay, dividends.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The lease was classified as an operating lease in accordance with the provisions of ASC 842, Leases , and discounted using an estimated incremental borrowing rate of 6.52 %.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The Company did not include the renewal option in considering the lease in accordance with the provisions of ASC 842 as the Company determined it was not likely to exercise the option, and discounted using an estimated incremental borrowing rate of 6.42 %.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

We remain highly focused on the enrollment of our registrational Phase 3 trials and the initiation of our first-in-human study of our BIM-DRS, which we expect to occur in the second half of 2026.

SEC original ↗SpyGlass Pharma, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026

All statements other than statements of historical fact contained in this Quarterly Report, including statements regarding our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans, or intentions relating to product candidates and markets and business trends are forward-looking statements.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

In some cases, you can identify forward-looking statements because they contain words such as may, will, should, expect, plan, anticipate, could, intend, target, project, contemplate, believe, estimate, predict, potential , aim or continue or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

University of Colorado License Agreement In March 2020, the Company entered into a license agreement with the Regents of the University of Colorado, which was amended in December of 2020, May of 2023 and October of 2025, under which the Company obtained an exclusive, royalty-bearing, sublicensable, worldwide license under a patent application co-owned by the University of Colorado and the Company relating to an intra-ocular drug dispenser and all patents claiming priority to such patent to develop, manufacture, and commercialize products for use in the treatment of various ophthalmic diseases.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

In making such determination, the Company considers all available positive and negative evidence quarterly, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including those set forth in the Risk Factors section of the Company s Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 filed with the Securities and Exchange Commission on or about the date hereof, and in similar disclosures set forth in the other documents that SpyGlass Pharma may file from time to time with the SEC.

SEC original ↗SpyGlass Pharma, Inc. — Earnings release (8-K exhibit)EX-99May 14, 2026

These statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors, including those described in the section titled Risk Factors and elsewhere in this Quarterly Report.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

New risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

In addition, significant changes in the biotechnology industry or the approval of competitive products or therapies could adversely affect the Company s development and operating results.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The terms of any future financing may adversely affect the holdings or the rights of the Company s existing stockholders.

SEC original ↗SpyGlass Pharma, Inc. — 10-Q Quarterly report10-QAug 6, 2026